scispace - formally typeset
Open accessJournalISSN: 2227-9059

Biomedicines

About: Biomedicines is an academic journal. The journal publishes majorly in the area(s): Cancer & Population. It has an ISSN identifier of 2227-9059. It is also open access. Over the lifetime, 2780 publication(s) have been published receiving 13011 citation(s).

...read more

Topics: Cancer, Population, Inflammation ...read more
Papers
  More

Open accessJournal ArticleDOI: 10.3390/BIOMEDICINES6030091
Bahare Salehi1, Abhay Prakash Mishra2, Manisha Nigam2, Bilge Sener3  +6 moreInstitutions (7)
09 Sep 2018-Biomedicines
Abstract: Resveratrol (3,5,4′-trihydroxy-trans-stilbene) belongs to polyphenols’ stilbenoids group, possessing two phenol rings linked to each other by an ethylene bridge. This natural polyphenol has been detected in more than 70 plant species, especially in grapes’ skin and seeds, and was found in discrete amounts in red wines and various human foods. It is a phytoalexin that acts against pathogens, including bacteria and fungi. As a natural food ingredient, numerous studies have demonstrated that resveratrol possesses a very high antioxidant potential. Resveratrol also exhibit antitumor activity, and is considered a potential candidate for prevention and treatment of several types of cancer. Indeed, resveratrol anticancer properties have been confirmed by many in vitro and in vivo studies, which shows that resveratrol is able to inhibit all carcinogenesis stages (e.g., initiation, promotion and progression). Even more, other bioactive effects, namely as anti-inflammatory, anticarcinogenic, cardioprotective, vasorelaxant, phytoestrogenic and neuroprotective have also been reported. Nonetheless, resveratrol application is still being a major challenge for pharmaceutical industry, due to its poor solubility and bioavailability, as well as adverse effects. In this sense, this review summarized current data on resveratrol pharmacological effects.

...read more

Topics: Resveratrol (64%)

279 Citations


Open accessJournal ArticleDOI: 10.3390/BIOMEDICINES5020034
Mehdi Rajabi1, Shaker A. Mousa1Institutions (1)
21 Jun 2017-Biomedicines
Abstract: A number of anti-angiogenesis drugs have been FDA-approved and are being used in cancer treatment, and a number of other agents are in different stages of clinical development or in preclinical evaluation. However, pharmacologic anti-angiogenesis strategies that arrest tumor progression might not be enough to eradicate tumors. Decreased anti-angiogenesis activity in single mechanism-based anti-angiogenic strategies is due to the redundancy, multiplicity, and development of compensatory mechanism by which blood vessels are remodeled. Improving anti-angiogenesis drug efficacy will require identification of broad-spectrum anti-angiogenesis targets. These strategies may have novel features, such as increased porosity, and are the result of complex interactions among endothelial cells, extracellular matrix proteins, growth factors, pericyte, and smooth muscle cells. Thus, combinations of anti-angiogenic drugs and other anticancer strategies such as chemotherapy appear essential for optimal outcome in cancer patients. This review will focus on the role of anti-angiogenesis strategies in cancer treatment.

...read more

Topics: Angiogenesis (54%), Cancer (54%), Tumor progression (51%)

263 Citations


Open accessJournal ArticleDOI: 10.3390/BIOMEDICINES4030014
Adam C. Parslow, Sagun Parakh1, Fook-Thean Lee, Hui K Gan  +1 moreInstitutions (1)
11 Jul 2016-Biomedicines
Abstract: Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.

...read more

Topics: Antibody-drug conjugate (57%)

127 Citations


Open accessJournal ArticleDOI: 10.3390/BIOMEDICINES6030082
Yu Rou Puar1, Muthu K. Shanmugam1, Lu Fan1, Frank Arfuso2  +4 moreInstitutions (4)
27 Jul 2018-Biomedicines
Abstract: Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is responsible for the regulation of a large number of genes that are involved in important physiological processes, including survival, inflammation, and immune responses. At the same time, this transcription factor can control the expression of a plethora of genes that promote tumor cell proliferation, survival, metastasis, inflammation, invasion, and angiogenesis. The aberrant activation of this transcription factor has been observed in several types of cancer and is known to contribute to aggressive tumor growth and resistance to therapeutic treatment. Although NF-κB has been identified to be a major contributor to cancer initiation and development, there is evidence revealing its role in tumor suppression. This review briefly highlights the major mechanisms of NF-κB activation, the role of NF-κB in tumor promotion and suppression, as well as a few important pharmacological strategies that have been developed to modulate NF-κB function.

...read more

Topics: Tumor promotion (57%), Transcription factor (56%), Cancer (52%) ...read more

116 Citations


Open accessJournal ArticleDOI: 10.3390/BIOMEDICINES5020021
Laura D'Ignazio1, Michael Batie1, Sonia Rocha1Institutions (1)
09 May 2017-Biomedicines
Abstract: Cancer is often characterised by the presence of hypoxia and inflammation. Paramount to the mechanisms controlling cellular responses under such stress stimuli, are the transcription factor families of Hypoxia Inducible Factor (HIF) and Nuclear Factor of κ-light-chain-enhancer of activated B cells (NF-κB). Although, a detailed understating of how these transcription factors respond to their cognate stimulus is well established, it is now appreciated that HIF and NF-κB undergo extensive crosstalk, in particular in pathological situations such as cancer. Here, we focus on the current knowledge on how HIF is activated by inflammation and how NF-κB is modulated by hypoxia. We summarise the evidence for the possible mechanism behind this activation and how HIF and NF-κB function impacts cancer, focusing on colorectal, breast and lung cancer. We discuss possible new points of therapeutic intervention aiming to harness the current understanding of the HIF-NF-κB crosstalk.

...read more

97 Citations


Performance
Metrics
No. of papers from the Journal in previous years
YearPapers
20211,763
2020659
201999
2018116
201773
201627

Top Attributes

Show by:

Journal's top 5 most impactful authors

Matteo Nicola Dario Di Minno

6 papers, 9 citations

Stefan Barth

4 papers, 77 citations

Shivan Chetty

4 papers, 77 citations

Martin Wawruch

3 papers, 1 citations

Barbara Kaltschmidt

3 papers, 57 citations

Network Information
Related Journals (5)
Cells

8.2K papers, 77.7K citations

91% related
International Journal of Molecular Sciences

45.3K papers, 715.6K citations

90% related
Cancers

13.4K papers, 128.6K citations

88% related
Biology

2.1K papers, 18.3K citations

85% related
Pharmaceuticals

1.3K papers, 21.3K citations

85% related